跳至主要内容
临床试验/CTRI/2012/04/002577
CTRI/2012/04/002577招募中2 期

Clinical Evaluation of Bilvadi Lehya in the Management of Irritable Bowel Syndrome (IBS) - IMCRP â?? IBS â?? 2010 - 2011

Central Council for Research in Ayurvedic Sciences CCRAS0 个研究点目标入组 150 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Known case of IBS as per Rome III criteria :
  • (Symptoms of recurrent abdominal pain or discomfort and a marked change in bowel habit for atleast six months, with symptoms experienced on atleast 3 days/month in the last 3 months associated with two or more of the following:
  • Pain is relieved by defecation
  • Onset associated with change of frequencey of stools
  • Onset assoicated with a change in form (appearance) of stools.
  • (Diagnosis to be confirmed by using the IBS module questionnaire)
  • 2.Willing and able to participate in the study

排除标准

  • 1. Patients with bleeding per rectum.
  • 2. Mixed infection with parasites like round worms, hook worms etc.
  • 3. Patients with evidence of malignancy
  • 4. Patients with Diabetes Mellitus {B.S. (F) > 126 mg% and / or B.S. (2 hr. PP) >200 mg% OR HbA1c > 6.5%}.
  • 5. Patient with poorly controlled Hypertension ( > 160 / 100 mm Hg)
  • 6. Patients on prolonged ( > 6 weeks) medication with corticosteoids, antidepressants, anticholinergics, etc. or any other drugs that may have an influence on the outcome of the study.
  • 7. Patients suffering from major systemic illness necessitating long term drug
  • treatment (Rheumatoid arthritis, Tuberculosis, Psycho-Neuro-Endocrinal disorders, etc.)
  • 8. Patients who have a past history of Atrial Fibrillation, Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months.
  • 9. Symptomatic patient with clinical evidence of Heart failure.
  • 10. Patients with concurrent serious hepatic disorder (defined as Aspartate Amino Transferase (AST) and / or Alanine Amino Transferase (ALT), Total Bilirubin, Alkaline Phosphatase (ALP) > 2 times upper normal limit) or Renal Disorders (defined as S. Creatinine >1.2mg/dL), Severe Pulmonary Dysfunction (uncontrolled Bronchial Asthma and / or Chronic Obstructive Pulmonary Disease [COPD]), or any other condition that may jeopardize the study.
  • 11. Alcoholics and/or drug abusers.
  • 12. H/o hypersensitivity to the trial drug or any of its ingredients.
  • 13. Pregnant / lactating woman.
  • 14. Patients who have completed participation in any other clinical trial during the past six (06) months.
  • 15. Any other condition which the Principal Investigator thinks may jeopardize the study.

研究者

发起方
Central Council for Research in Ayurvedic Sciences CCRAS

相似试验